More importantly, targeting the galectin-9/Dectin-1 axis with an exosome-based dual delivery biosystem can reverse the immunosuppression of M2-like TAMs and enhance anti-tumour immunity, suggesting that Dectin-1 is a valuable target for cancer immunotherapy [21]. Here, CLEC7A is linked to neoplasm.